Results 221 to 230 of about 3,436,403 (377)
Molecular Oncology, EarlyView.This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani +14 more
wiley +1 more source
Molecular Oncology, EarlyView.B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez +17 more
wiley +1 more source
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
Molecular Oncology, EarlyView.In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley +1 more source
Book review of “Here, there, everywhere—A memoir” by Peter Almond
, 2022 Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022.
Bruce J. Gerbi
wiley +1 more source
PROTOCOL: Cost‐benefit analysis and cost‐effectiveness of sentencing: A systematic review of the literature [PDF]
, 2003 Cynthia McDougall +3 more
openalex +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Pharmacists' perceptions regarding their contribution to improving the public's health: a systematic review of the United Kingdom and international literature 1990–2001 [PDF]
, 2003 Claire Anderson +2 more
openalex +1 more source
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen +12 more
wiley +1 more source
Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?
Molecular Oncology, EarlyView.Chen‐xi Li, Zhong‐cheng Gong
wiley +1 more source
A systematic literature review on the role of the forensic nursing. [PDF]
J Educ Health PromotTabanejad Z, Ebadi A, Banazadeh M.
europepmc +1 more source